Incanthera
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $4.7M
Overview
Developing oral targeted therapies for solid tumor cancers.
Oncology
Technology Platform
Focuses on developing orally bioavailable small molecules that inhibit key signaling pathways in cancer cells.
Funding History
2Total raised:$4.7M
Series A$3.5M
Seed$1.2M
Opportunities
Positive Phase 2 data could lead to lucrative licensing deals or partnerships with larger oncology-focused companies.
Risk Factors
As a small public company, it carries significant financing and execution risk, with clinical failure potentially impacting its viability.
Competitive Landscape
Faces intense competition in solid tumor oncology from large pharma and numerous biotechs with more advanced and resourced programs.